[ Back to EurekAlert! ]

Contact: David Orenstein
Brown University

Bapineuzumab and Placebo

Caption: DAD (Disability Assessment for Dementia) scores worsened on average during the 78-week trial, with "bapi" (dotted blue line) showing no improvement over placebo. This data is from the trial with APOE allele carriers.

Credit: Salloway et. al.

Usage Restrictions: with credit

Related news release: Disappointing Alzheimer's trial yields new ideas

[ Back to EurekAlert! ]